PDF(Pubmed)
Abstract：
This study was conducted to determine the prevalence of prolonged neuromuscular symptoms, including fatigue, anosmia, headache, myalgia, and joint pain in COVID-19 survivors hospitalized with mild, moderate, or severe infections worldwide. The search was conducted up to January 30th, 2021 using three databases (PubMed, Scopus, and Web of Science) to identify potentially eligible studies. Data on study characteristics, follow-up characteristics, and severity of COVID-19 during hospitalization were collected in accordance with PRISMA guidelines. The Newcastle-Ottawa scale was used to assess the quality of relevant articles. The estimated prevalence of specific prolonged neuromuscular symptoms and the association between COVID-19 severity and occurrence of prolonged neuromuscular symptoms was analyzed wherever appropriate. Database search yielded 4,050 articles and 22 articles were included for meta-analysis. The estimated prevalence of prolonged fatigue was recorded in 21.2% (95%CI: 11.9%- 34.8%) of 3,730 COVID-19 survivors. Persistent anosmia was recorded in 239 of 2,600 COVID-19 survivors (9.7%, 95%CI: 6.1%-15.2%). In 84 out of 2,412 COVID-19 survivors (8.9%, 95%CI: 3.2%-22.6%), prolonged headache was observed. A total of 53 out of 1,125 COVID-19 patients (5.6%, 95%CI: 2.1%-14.2%) complained of persistent myalgia even after being discharged from the hospital. The prevalence of prolonged joint pain was in 15.4% (95%CI: 8.2%-27.2%) of subjects. Due to data scarcity on COVID-19 severity and prolonged neuromuscular symptoms, association analysis could not be conducted. Widespread concern regarding long-term impacts of COVID-19 was raised after several studies reported prolonged symptoms in COVID-19 survivors. Numerous theories have been proposed to address this concern; however, as the research on this pandemic is still ongoing, no explanation is definitive yet. Therefore, follow-up studies in COVID-19 survivors after recovery from COVID-19 are warranted to determine the pathogenesis of prolonged symptoms. PROSPERO registration: CRD42021242332.
摘要：
这项研究是为了确定长期神经肌肉症状的患病率，包括疲劳,嗅觉缺失,头痛,肌痛，轻度住院的COVID-19幸存者的关节痛，中度,或全球严重感染。搜索一直进行到1月30日，2021年使用三个数据库(PubMed，Scopus,和WebofScience）以确定潜在的合格研究。有关研究特征的数据，后续特点,根据PRISMA指南收集住院期间COVID-19的严重程度。纽卡斯尔-渥太华量表用于评估相关文章的质量。在适当的情况下分析了特定延长神经肌肉症状的估计患病率以及COVID-19严重程度与延长神经肌肉症状发生之间的关系。数据库搜索产生4,050篇文章，其中22篇文章被纳入荟萃分析。在3,730名COVID-19幸存者中，估计的长期疲劳患病率为21.2％（95CI：11.9％-34.8％）。在2,600名COVID-19幸存者中，有239名记录到持续的失语症（9.7%，95CI：6.1%-15.2%）。在2,412名COVID-19幸存者中，有84人（8.9%，95CI：3.2%-22.6%），观察到长时间的头痛。在1,125例COVID-19患者中，共有53例（5.6%，95CI：2.1％-14.2％）即使在出院后仍抱怨持续性肌痛。长期关节痛的患病率为15.4%(95CI:8.2%-27.2%)。由于COVID-19严重程度和长期神经肌肉症状的数据匮乏，无法进行关联分析。在几项研究报告COVID-19幸存者出现长期症状后，人们普遍关注COVID-19的长期影响。已经提出了许多理论来解决这一问题；然而，由于对这种流行病的研究仍在进行中，还没有明确的解释。因此,有必要对COVID-19康复后的COVID-19幸存者进行随访研究，以确定长期症状的发病机制。PROSPERO注册：CRD42021242332。
